Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 January 2020 | Story Valentino Ndaba | Photo Anja Aucamp
Glolooks
Refilwe Xaba, the founder and CEO of Glolooks.

Refilwe Xaba, Senior Assistant Officer in Entrepreneurship Development at the UFS Centre for Development Support, is the founder and CEO of Glolooks. This Bloemfontein-based company manufactures and supplies an organic, natural hair product range.

When she first developed the products, they were for personal use. Xaba evolved from an intrapreneur to an entrepreneur. She innovated a personal solution into a booming business idea. It was only in May 2016 that she decided to go into business, following growing interest in the way she maintained her hair. “I officially started in-depth research in October 2015, after years of making concoctions for myself.”


Business and books

Xaba reckons that a research background is beneficial for growing a business such as Glolooks that has a huge technical aspect. She is currently pursuing her PhD in Entrepreneurship with a focus on marketing and is planning to use her business as a case study.

Her undergraduate, honours, and master’s studies, which she completed at Kovsies, contributed to equipping Xaba with skills to grow her business. She believes in balancing education and business. “I have always been commerce-orientated. If there is a problem to be fixed, I fix it. However, people are at the centre of my heart.”


Growing Glolooks

In 2019, Glolooks opened a salon in Westdene, where customers can receive a holistic experience above and beyond merely purchasing the product. Xaba says this is one of the ways her business is being innovative when it comes to creating relationships with customers.

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept